U.S. Markets open in 9 hrs 27 mins
  • S&P Futures

    4,387.75
    -6.00 (-0.14%)
     
  • Dow Futures

    34,833.00
    -1.00 (-0.00%)
     
  • Nasdaq Futures

    14,965.25
    -46.25 (-0.31%)
     
  • Russell 2000 Futures

    2,224.00
    +3.30 (+0.15%)
     
  • Crude Oil

    72.64
    +0.25 (+0.35%)
     
  • Gold

    1,814.30
    +14.60 (+0.81%)
     
  • Silver

    25.25
    +0.38 (+1.52%)
     
  • EUR/USD

    1.1861
    +0.0014 (+0.1186%)
     
  • 10-Yr Bond

    1.2610
    +0.0270 (+2.19%)
     
  • Vix

    18.31
    -1.05 (-5.42%)
     
  • GBP/USD

    1.3922
    +0.0014 (+0.0975%)
     
  • USD/JPY

    109.7840
    -0.1260 (-0.1146%)
     
  • BTC-USD

    39,682.96
    -217.66 (-0.55%)
     
  • CMC Crypto 200

    927.42
    -2.51 (-0.27%)
     
  • FTSE 100

    7,016.63
    +20.55 (+0.29%)
     
  • Nikkei 225

    27,755.69
    +174.03 (+0.63%)
     

Evelo Biosciences to Report Second Quarter 2021 Financial Results on Thursday, July 29, 2021

·1 min read

CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, July 29, 2021, to report its second quarter 2021 financial results and discuss business highlights.

To access the live conference call, please dial 866-795-3242 (domestic) or 409-937-8909 (international) and refer to conference ID 1658301. A live webcast of the event will also be available under “News and Events” in the Investors section of Evelo's website at http://ir.evelobio.com. The archived webcast will be available on Evelo's website approximately two hours after the completion of the event and will be available for 30 days following the call.

About Evelo Biosciences
Evelo Biosciences is a clinical stage biotechnology company developing orally delivered medicines that act on the small intestinal axis, SINTAX™, to have systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems.

Evelo currently has four product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases and EDP1908 for the treatment of cancer. Evelo is advancing additional product candidates in other disease areas.

For more information, please visit www.evelobio.com and engage with Evelo on LinkedIn.

Contact
Jessica Cotrone, 978-760-5622
jcotrone@evelobio.com